RVL Pharmaceuticals PLC
NASDAQ:RVLP
RVL Pharmaceuticals PLC
Gross Profit
RVL Pharmaceuticals PLC
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
RVL Pharmaceuticals PLC
NASDAQ:RVLP
|
Gross Profit
$40.3m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Gross Profit
$59.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Gross Profit
$34.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Gross Profit
$38.8B
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Merck & Co Inc
NYSE:MRK
|
Gross Profit
$46B
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
Eli Lilly and Co
NYSE:LLY
|
Gross Profit
$28.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
See Also
What is RVL Pharmaceuticals PLC's Gross Profit?
Gross Profit
40.3m
USD
Based on the financial report for Dec 31, 2022, RVL Pharmaceuticals PLC's Gross Profit amounts to 40.3m USD.
What is RVL Pharmaceuticals PLC's Gross Profit growth rate?
Gross Profit CAGR 5Y
-20%
Over the last year, the Gross Profit growth was 190%. The average annual Gross Profit growth rates for RVL Pharmaceuticals PLC have been -32% over the past three years , -20% over the past five years .